ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.80.

A number of brokerages recently commented on PRQR. Oppenheimer began coverage on ProQR Therapeutics in a research note on Thursday, March 12th. They issued an “outperform” rating and a $9.00 target price for the company. Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Tuesday. Finally, Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, April 9th.

Institutional Trading of ProQR Therapeutics

A number of large investors have recently bought and sold shares of PRQR. Aberdeen Group plc grew its position in ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after acquiring an additional 651,853 shares during the period. Ikarian Capital LLC grew its position in ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after acquiring an additional 600,000 shares during the period. Privium Fund Management B.V. grew its position in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after acquiring an additional 359,475 shares during the period. Citadel Advisors LLC grew its position in ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 277,749 shares during the period. Finally, Millennium Management LLC grew its position in ProQR Therapeutics by 80.8% in the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock valued at $879,000 after acquiring an additional 194,369 shares during the period. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Trading Down 4.9%

Shares of NASDAQ PRQR opened at $1.55 on Friday. The business has a fifty day simple moving average of $1.68 and a 200 day simple moving average of $1.96. The firm has a market capitalization of $163.31 million, a price-to-earnings ratio of -3.37 and a beta of 0.10. ProQR Therapeutics has a one year low of $1.33 and a one year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $5.53 million during the quarter, compared to analyst estimates of $6.12 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. On average, research analysts anticipate that ProQR Therapeutics will post -0.53 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.